BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9816102)

  • 1. p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis.
    Pappot H; Francis D; Brünner N; Grondahl-Hansen J; Osterlind K
    Clin Cancer Res; 1996 Jan; 2(1):155-60. PubMed ID: 9816102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
    Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis.
    Xu HJ; Cagle PT; Hu SX; Li J; Benedict WF
    Clin Cancer Res; 1996 Jul; 2(7):1169-76. PubMed ID: 9816284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
    Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
    Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B
    Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
    Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
    Pedersen H; Grøndahl-Hansen J; Francis D; Osterlind K; Hansen HH; Danø K; Brünner N
    Cancer Res; 1994 Jan; 54(1):120-3. PubMed ID: 8261432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
    Pavey SJ; Marsh NA; Ray MJ; Butler D; Dare AJ; Hawson GA
    Boll Soc Ital Biol Sper; 1996; 72(11-12):331-40. PubMed ID: 9178585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
    Pappot H; Pedersen AN; Brünner N; Christensen IJ
    Lung Cancer; 2006 Feb; 51(2):193-200. PubMed ID: 16325301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas.
    Mørkve O; Halvorsen OJ; Skjaerven R; Stangeland L; Gulsvik A; Laerum OD
    Anticancer Res; 1993; 13(3):571-8. PubMed ID: 8391242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer.
    Tan DF; Li Q; Rammath N; Beck A; Wiseman S; Anderson T; al-Salameh A; Brooks J; Bepler G
    Anticancer Res; 2003; 23(2C):1665-72. PubMed ID: 12820438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
    Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
    BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer.
    Offersen BV; Riisbro R; Knoop A; Brünner N; Overgaard J;
    Acta Oncol; 2007; 46(6):782-91. PubMed ID: 17653901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma.
    Törmänen U; Eerola AK; Rainio P; Vähäkangas K; Soini Y; Sormunen R; Bloigu R; Lehto VP; Pääkkö P
    Cancer Res; 1995 Dec; 55(23):5595-602. PubMed ID: 7585640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time.
    Ohsaki Y; Toyoshima E; Fujiuchi S; Matsui H; Hirata S; Miyokawa N; Kubo Y; Kikuchi K
    Clin Cancer Res; 1996 May; 2(5):915-20. PubMed ID: 9816250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.
    Ebina M; Steinberg SM; Mulshine JL; Linnoila RI
    Cancer Res; 1994 May; 54(9):2496-503. PubMed ID: 7909277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.